HK1178149A1 - Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4--- - Google Patents

Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---

Info

Publication number
HK1178149A1
HK1178149A1 HK13105060.9A HK13105060A HK1178149A1 HK 1178149 A1 HK1178149 A1 HK 1178149A1 HK 13105060 A HK13105060 A HK 13105060A HK 1178149 A1 HK1178149 A1 HK 1178149A1
Authority
HK
Hong Kong
Prior art keywords
pyrazol
heterocyclyl
methods
carboxamide compounds
carboxamide
Prior art date
Application number
HK13105060.9A
Other languages
English (en)
Chinese (zh)
Inventor
Xiaojing Wang
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44227838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1178149(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1178149A1 publication Critical patent/HK1178149A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK13105060.9A 2010-04-07 2013-04-26 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4--- HK1178149A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32158810P 2010-04-07 2010-04-07
PCT/EP2011/055300 WO2011124580A1 (en) 2010-04-07 2011-04-06 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Publications (1)

Publication Number Publication Date
HK1178149A1 true HK1178149A1 (en) 2013-09-06

Family

ID=44227838

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13105060.9A HK1178149A1 (en) 2010-04-07 2013-04-26 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---

Country Status (20)

Country Link
US (3) US8436001B2 (xx)
EP (1) EP2556066B1 (xx)
JP (2) JP6161537B2 (xx)
KR (1) KR101464060B1 (xx)
CN (1) CN102933572B (xx)
AU (1) AU2011237936A1 (xx)
BR (1) BR112012025480A2 (xx)
CA (1) CA2794801C (xx)
CL (1) CL2012002782A1 (xx)
CO (1) CO6630133A2 (xx)
CR (1) CR20120469A (xx)
EA (1) EA201290957A1 (xx)
ES (1) ES2601004T3 (xx)
HK (1) HK1178149A1 (xx)
IL (1) IL222227A0 (xx)
MA (1) MA34234B1 (xx)
MX (1) MX2012011533A (xx)
PE (1) PE20130405A1 (xx)
SG (1) SG184475A1 (xx)
WO (1) WO2011124580A1 (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013045461A1 (en) * 2011-09-27 2013-04-04 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EP2861585B1 (en) 2012-05-21 2019-01-09 Novartis AG Novel ring-substituted n-pyridinyl amides as kinase inhibitors
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
RS60202B1 (sr) * 2012-09-26 2020-06-30 Hoffmann La Roche Jedinjenja cikličnog etra pirazol-4-il-heterociklil-karboksamida i postupci primene
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
WO2014113388A1 (en) 2013-01-15 2014-07-24 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
PE20160532A1 (es) * 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
NZ631142A (en) * 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015068856A1 (en) * 2013-11-08 2015-05-14 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
JP6554480B2 (ja) * 2014-03-18 2019-07-31 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト オキセパン−２−イル−ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US10227343B2 (en) 2015-01-30 2019-03-12 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
LT3286181T (lt) * 2015-04-22 2021-04-26 Rigel Pharmaceuticals, Inc. Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
CN105254624B (zh) * 2015-09-18 2019-08-09 上海吉铠医药科技有限公司 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10414753B2 (en) 2016-10-26 2019-09-17 Rigel Pharmaceuticals, Inc. Amide compounds and method for making and using
EP3706735A1 (en) 2017-11-06 2020-09-16 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7268049B2 (ja) 2018-03-08 2023-05-02 インサイト・コーポレイション ＰＩ３Ｋ－γ阻害剤としてのアミノピラジンジオール化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN110452180A (zh) * 2019-06-25 2019-11-15 南京普锐达医药科技有限公司 一种合成2-氯-5-氨基-6-嘧啶甲酸乙酯的方法
CN114364674A (zh) 2019-08-30 2022-04-15 里格尔药品股份有限公司 吡唑化合物，其配制品以及使用所述化合物和/或配制品的方法
CN111087389B (zh) * 2019-12-03 2020-10-27 佳木斯大学 一种用于治疗胶质母细胞瘤的药物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2003006151A1 (en) 2001-07-12 2003-01-23 Avecia Limited Microencapsulated catalyst, methods of preparation and methods of use thereof
RU2342365C2 (ru) * 2003-05-01 2008-12-27 Бристол-Маерс Сквибб Компани Арилзамещенные пиразоламиды в качестве ингибиторов киназ
MX2007001727A (es) * 2004-08-13 2007-04-20 Genentech Inc Compuestos a base de 2-amido-tiazol que exhiben actividad inhibidora de enzima que utiliza atp y composiciones y usos de los mismos.
CN104892582B (zh) 2005-10-07 2019-09-27 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
FR2903406B1 (fr) 2006-07-04 2012-08-10 Aventis Pharma Sa Derives de pyrazolylbenzimidazole,compositions les contenant et utilisation
US20100021420A1 (en) 2006-07-14 2010-01-28 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
EP2049106A2 (en) 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations
EP2046327A1 (en) 2006-07-21 2009-04-15 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
MX2009004791A (es) 2006-10-31 2009-08-19 Schering Corp Derivados de anilinopiperazina t metodos de uso de los mismos.
EP2078003B1 (en) * 2006-10-31 2017-03-08 Merck Sharp & Dohme Corp. Anilinopiperazine derivatives and methods of use thereof
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
KR101514853B1 (ko) 2007-03-01 2015-04-24 노파르티스 아게 Ｐｉｍ 키나제 억제제 및 이들의 사용 방법
CZ201016A3 (cs) * 2007-06-22 2010-06-23 Opynen@Adam Van Nástavec pro rozširovac trubek, sestava pro ovládání rozširovace trubek a zpusob využívání tohoto rozširovace trubek
RU2474580C2 (ru) * 2007-07-19 2013-02-10 Шеринг Корпорейшн Гетероциклические амидные соединения как ингибиторы протеинкиназ
PL2206707T3 (pl) 2007-10-24 2015-01-30 Astellas Pharma Inc Związek azolokarboksamidowy lub jego sól
JP5230035B2 (ja) * 2007-10-29 2013-07-10 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としてのチアゾール誘導体
WO2009058730A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Diamido thiazole derivatives as protein kinase inhibitors
CN101910163A (zh) * 2007-10-29 2010-12-08 先灵公司 杂环脲和硫脲衍生物及其用法
EP2070924A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel
EP2070916A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
CA2712959C (en) 2008-01-22 2015-06-23 Vernalis (R & D) Ltd Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
AR070531A1 (es) 2008-03-03 2010-04-14 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
WO2009119088A1 (ja) * 2008-03-25 2009-10-01 武田薬品工業株式会社 複素環化合物
PT2344474E (pt) * 2008-09-02 2015-12-28 Novartis Ag Derivados de picolinamida como inibidores de cinase
WO2011000020A1 (en) 2009-06-12 2011-01-06 Sbc Research Pty Ltd Enhanced method of detection
UA110324C2 (xx) 2009-07-02 2015-12-25 Genentech Inc Інгібуючі jak сполуки на основі піразолопіримідину
JP5567136B2 (ja) * 2009-09-08 2014-08-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ４−置換ピリジン−３−イル−カルボキサミド化合物及び使用方法
RU2012121633A (ru) 2009-10-22 2013-11-27 Вандербилт Юниверсити АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds

Also Published As

Publication number Publication date
WO2011124580A1 (en) 2011-10-13
EP2556066B1 (en) 2016-10-19
CO6630133A2 (es) 2013-03-01
CA2794801C (en) 2019-01-15
CR20120469A (es) 2012-11-30
JP6161537B2 (ja) 2017-07-12
US9573943B2 (en) 2017-02-21
JP2013523798A (ja) 2013-06-17
US20110251176A1 (en) 2011-10-13
CN102933572A (zh) 2013-02-13
US20140128376A1 (en) 2014-05-08
MA34234B1 (fr) 2013-05-02
JP2016040281A (ja) 2016-03-24
KR20130001309A (ko) 2013-01-03
PE20130405A1 (es) 2013-04-10
SG184475A1 (en) 2012-11-29
US8669361B2 (en) 2014-03-11
ES2601004T3 (es) 2017-02-13
BR112012025480A2 (pt) 2020-08-18
US20130203732A1 (en) 2013-08-08
AU2011237936A1 (en) 2012-10-11
US8436001B2 (en) 2013-05-07
EA201290957A1 (ru) 2013-04-30
CN102933572B (zh) 2015-01-07
CA2794801A1 (en) 2011-10-13
IL222227A0 (en) 2012-12-31
MX2012011533A (es) 2012-12-17
KR101464060B1 (ko) 2014-11-20
EP2556066A1 (en) 2013-02-13
CL2012002782A1 (es) 2013-01-18

Similar Documents

Publication Publication Date Title
IL266168A (en) Heteroaryl compounds and methods of their use
HK1243417A1 (zh) 吡啶酮和氮雜吡啶酮化合物及使用方法
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
EP2536756A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2584897A4 (en) COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE
PT2539136T (pt) Poste de barreira e método de fabrico do mesmo
EP2772483A4 (en) 4-AMINOCARBAZOLE COMPOUND AND USE THEREOF
EP2663565A4 (en) HEZEROARYL COMPOUNDS AND METHOD FOR USE THEREOF
EP2536283A4 (en) PHENYLHETEROARYL DERIVATIVES AND USE METHOD THEREFOR
EP2596112A4 (en) ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
ZA201206456B (en) Uses of dgati inhibitors
IL220812A0 (en) Compounds and methods
EP2523560A4 (en) CONNECTIONS AND METHODS
EP2558496A4 (en) ANTIBODIES TO POLYUBIQUITINE AND METHOD FOR THEIR USE
IL256026B (en) Treatment methods
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2611791A4 (en) OLIGOOXOPIPERAZINES AND METHODS FOR THEIR PREPARATION AND USE
GB201115521D0 (en) Colorant-polyesters and methods of producing colorant-polyesters

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200401